Pharmaceuticals

Iterum Therap

Maxim Group Analyst Maintains Buy Rating on Iterum Therapeutics, Lows Price Target to $2

Iterum Therapeutics Third Quarter Earnings Call Shows Orlynda Market Performance

Iterum Therapeutics released FY2025 Q3 earnings on November 14 Pre-Market EST, actual revenue USD 390K (forecast USD 0), actual EPS USD -0.196 (forecast USD -0.09)

Iterum Therapeutics released FY2025 9 Months Earnings on November 14 Pre-Market EST, with actual revenue of USD 390K and EPS of USD -0.5026

Iterum Therapeutics to Release FY2025 Q3 Earnings on November 14, Pre-Market EST, Forecasted Revenue USD 0, EPS USD -0.09

McCarthy Focusing on Healthcare Sector and Specific Stocks

Iterum Therapeutics released FY2025 Semi-Annual earnings on August 5 Pre-Market (EST), actual revenue USD 0, actual EPS USD -0.3079

Iterum Therapeutics released FY2025 Q2 earnings on August 5 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1629 (forecast USD -0.11)

Iterum Therapeutics to Release FY2025 Q2 Earnings on August 5, Pre-Market EST, Forecast EPS USD -0.11

Iterum Therapeutics announces to combat multidrug-resistant pathogens

Iterum Therapeutics Appoints Christine Coyne As Chief Commercial Officer

Iterum Therapeutics and Eversana Sign ORLYNVAHTM Promotion Agreement

Iterum Therapeutics released FY2025 Q1 earnings on May 13 Pre-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1436 (forecast USD -0.14)

Iterum Therapeutics PLC Prepares for Q4 2025 Orlynvah(TM) Launch

Iterum Therapeutics to Report Quarterly Earnings

Iterum Therapeutics to release FY2025 Q1 earnings on May 13 Pre-Market EST, forecast revenue USD 2.683 M, EPS USD -0.15

Iterum Therapeutics released FY2024 Annual Earnings on February 7 During-Market (EST), Actual Revenue: 0 USD (Forecast: 0 USD), Actual EPS: -1.26 USD (Forecast: -1.15 USD)

Iterum Therapeutics released FY2024 Q4 earnings on February 7, 2025, during market hours (EST), with actual revenue of 0 USD (forecast 0 USD) and actual EPS of -0.2483 USD (forecast -0.17 USD)

Iterum Therapeutics to Release FY2024 Q4 Earnings on February 7, 2025, During Market Hours EST, Forecasted EPS -0.17 USD

Iterum Therapeutics released FY2024 Cumulative 3Q earnings on November 14 Pre-Market (EST), with actual revenue of 0 and EPS of -1.066

Vision Marine Tech

AMC Robotics

SRX Health Solutions

Venus Concept

Cementos Pacasmayo Saa 

Biodexa Pharmaceuticals

ChowChow Cloud

Everbright Digital

Aldeyra Therap

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

Eli Lilly

Roche

ROCHE HOLDINGS AG

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap